Department of Pharmacology Archives

Melanoma treatment response

Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

VUMC researchers find clue to drug-induced arrhythmias

Feb. 24, 2022—Vanderbilt University Medical Center researchers have made a fundamental discovery about how the heart compensates for genetic variations that otherwise could trigger abnormal and potentially fatal heart rhythms.

Seven from VUMC among most highly cited researchers

Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Marnett stepping down as dean of VUSM Basic Sciences

Oct. 12, 2021—Lawrence Marnett, PhD, who has served as dean of Vanderbilt University’s School of Medicine Basic Sciences since its creation in 2016, will step down as dean effective June 30, 2022.

Potential protection from atherosclerosis

Aug. 19, 2021—Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

American Heart Association honors Biaggioni’s research

Aug. 5, 2021—Italo Biaggioni, MD, professor of Medicine and Pharmacology, has been selected as a Distinguished Scientist of the American Heart Association for his contributions to cardiovascular and stroke research.

From left, MacRae Linton, MD, Huan Tao, MD, PhD, Jonathan Brown, MD, and colleagues have discovered a potential new target for preventing atherosclerosis.

Nature’s “recycler” could reduce heart disease risk: study

Jul. 8, 2021—Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

Benjamin Brown, left, Jens Meiler, PhD, Zhenfang Du, PhD, and colleagues are studying the functional consequences of genetic mutations and how those changes can drive cancerous growth.

Personalized Structural Biology aids cancer treatment decisions

Apr. 8, 2021—Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.

NIH grant bolsters research on heart disease, cholesterol

Jan. 21, 2021—Thanks to major funding from the National Institutes of Health (NIH), researchers at Vanderbilt University Medical Center have made major inroads in understanding how high-density lipoprotein (HDL), commonly known as good cholesterol, in some cases may actually contribute to the development of atherosclerosis.

Ann Richmond, MD, Chi Yan, PhD, Jinming Yang, PhD, and colleagues are studying ways to boost antitumor immunity and reduce tumor growth in breast cancer and melanoma.

Study reveals new strategy for reducing tumor growth, metastasis

Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

Lindsley to direct Center for Neuroscience Drug Discovery

Oct. 22, 2020—Craig Lindsley, PhD, the William K. Warren Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery (WCNDD), effective Dec. 1. Lindsley assumes the director position from Jeffrey Conn, PhD, Lee. E. Limbird Chair in Pharmacology and professor of Pharmacology.